🇺🇸 FDA
Patent

US 6592872

Targeting antigens to the MHC class I processing pathway with an anthrax toxin fusion protein

expired A61KA61K39/00

Quick answer

US patent 6592872 (Targeting antigens to the MHC class I processing pathway with an anthrax toxin fusion protein) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Jul 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Jul 15 2003 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K39/00